Healthcare Stocks Draw Contrasting Analyst Views

Analysts have expressed conflicting views on several healthcare companies, including Amylyx Pharmaceuticals Inc (AMLX), Moderna (MRNA), and Merck & Company (MRK).

Amylyx Pharmaceuticals has an analyst consensus of Strong Buy with a price target consensus of $42.75, a 42.9% upside from current levels. Joseph Thome from TD Cowen maintained a Buy rating on the company, citing its potential for growth.

However, Jessica Fye from J.P. Morgan maintained a Sell rating on Moderna, with a price target of $40.00. The analyst consensus on Moderna is a Hold, with an average price target of $48.92.

J.P. Morgan analyst Chris Schott maintained a Buy rating on Merck & Company, despite the company's current market value exceeding its price target of $138.60.